Hospital stocks like Apollo Hospitals, Fortis Healthcare, and Max Healthcare are under pressure due to concerns raised by the Supreme Court about high mark-ups on medicines sold by private hospitals. The court has asked the government to examine the issue, including the possibility of setting a uniform margin on medicines to reduce excessive pricing and ease the burden on patients.
- The Supreme Court highlighted extreme price differences on cancer drugs, with some medicines sold at ten times their supply price.
- Concerns exist over hospitals requiring patients to buy medicines only from their in-house pharmacies.
- Medicine pricing changes could impact hospital revenues and profitability significantly.
- Most analysts view the recent stock correction as short-term amid strong hospital sector fundamentals.
- The next Supreme Court hearing on this matter is scheduled for October 12, 2026.
Why Are Hospital Stocks Facing Selling Pressure?
The selling pressure on hospital stocks follows the Supreme Court's concerns about steep mark-ups on medicines, especially cancer drugs, sold by private hospitals. The court cited an example where a cancer drug supplied at around ₹2,700 was sold at nearly ₹27,000. This has raised questions about the fairness of pricing and the financial impact on patients and taxpayers.
What Is the Supreme Court Asking the Government to Do?
The Supreme Court has asked the government to consider whether a uniform 16% margin should be allowed on medicines to control excessive pricing. The court is also examining if corporate hospitals limit patients’ access to cheaper medicines by requiring purchases from their own pharmacies. The issue is part of ongoing petitions seeking stricter price controls under the Drugs (Prices Control) Order (DPCO).
How Could This Affect Hospital Revenues and Profitability?
Medicines, consumables, and implants make up about 21% of private hospital revenues. Changes in medicine pricing could significantly affect profitability. For example, Macquarie estimates potential earnings impacts ranging from high single digits to double digits in EBITDA. Hospitals might offset some losses by repricing treatment packages and other services.
What Are Analysts Saying About the Situation?
Despite the regulatory concerns, many analysts remain broadly positive about Indian hospital stocks. BofA and Jefferies see the recent correction as likely short-lived and maintain Buy ratings on Apollo and Fortis. HSBC acknowledges pricing control as a risk but is uncertain about actual changes. Axis Capital believes the extreme mark-up example is an exception and expects some regulatory recommendations to be considered.
When Will the Issue Be Decided?
The Supreme Court has scheduled the next hearing on this matter for October 12, 2026. Investors and market watchers will be closely following developments to understand how regulations might change medicine pricing and affect hospital businesses.
Frequently Asked Questions
Q: Why did the Supreme Court intervene in medicine pricing?
A: The court intervened due to concerns about very high mark-ups on medicines, especially cancer drugs, which can burden patients financially.
Q: What is a uniform margin on medicines?
A: A uniform margin means setting a fixed percentage limit on the profit hospitals can make from selling medicines, to prevent excessive pricing.
Q: How much of hospital revenue comes from medicines?
A: Medicines, consumables, and implants typically account for about 21% of private hospital revenues.
Q: Are analysts worried about the hospital sector?
A: While there is concern about regulatory risks, most analysts remain constructive and view recent stock declines as potential buying opportunities.
Q: When will there be more clarity on this issue?
A: The next Supreme Court hearing is on October 12, 2026, which may provide further guidance on medicine pricing regulations.
